Probiotic supplementation with Lactobacillus plantarum and Pediococcus acidilactici for Helicobacter pylori therapy: A randomized, double‐blind, placebo‐controlled trial. Issue 5 (23rd August 2018)

• Record Type: Journal Article
• Authors: McNicholl, Adrian G.; Molina‐Infante, Javier; Lucendo, Alfredo J.; Calleja, José Luis; Pérez‐Aisa, Ángeles; Modolell, Inés; Aldeguer, Xavier; Calafat, Margalida; Comino, Luis; Ramas, Mercedes; Callejo, Ángel; Badiola, Carlos; Serra, Jordi; Gisbert, Javier P.
• Is Part Of: Helicobacter. Volume 23:Issue 5(2018)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2018-08-23
• Subjects: H. pylori -- Lactobacillus plantarum -- Pediococcus acidilactici -- probiotics -- randomized clinical trial; Helicobacter -- Periodicals; Helicobacter infections -- Periodicals; Stomach -- Diseases -- Periodicals; 616.3301405
• DOI: 10.1111/hel.12529
• Languages: English
• ISSNs: 1083-4389

Abstract

Abstract: Objective: To evaluate the safety, tolerability and efficacy of a probiotic supplementation for Helicobacter pylori (H. pylori) eradication therapy. Design: Consecutive adult naive patients with a diagnosis of H. pylori infection who were prescribed eradication therapy according to clinical practice (10‐day triple or nonbismuth quadruple concomitant therapy) randomly received probiotics (1 × 10 9 colony‐forming units each strain, Lactobacillus plantarum and Pediococcus acidilactici ) or matching placebo. Side effects at the end of the treatment, measured through a modified De Boer Scale, were the primary outcome. Secondary outcomes were compliance with therapy and eradication rates. Results: A total of 209 patients (33% triple therapy, 66% non‐bismuth quadruple therapy) were included [placebo (n = 106) or probiotic (n = 103)]. No differences were observed regarding side effects at the end of the treatment between groups (β −0.023, P 0.738). Female gender ( P < 0.001) and quadruple therapy ( P 0.007) were independent predictors of side effects. No differences in compliance were observed, regardless of the study group or eradication therapy. Eradication rates were similar between groups [placebo 95% (95% confidence interval (CI), 89% to 98%) vs probiotic 97% (95% CI, 92% to 99%), P 0.721]. There were no relevant differences in cure rates (>90% in all cases) between triple and quadruple concomitant therapy. Conclusion: Probiotic supplementation containing Lactobacillus Plantarum and Pediococcus acidilactici to H. pylori treatment neither decreased side effects nor improved compliance with therapy or eradication rates.